Beam's CEO said top-line sickle cell data were positive, keeping a BLA filing on track for as early as December.
BEAM · Beam Therapeutics Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 52%
- Last earnings
- Oct 27, 2026
- Latest filing
- 10-Q · Nov 3
- Price history
- Feb 2020 to Nov 2026
Up next
Latest documents
Beam Therapeutics plans to submit a biologics license application (BLA) for risto-cel as early as year-end 2026, after completing dosing for all adult and adolescent patients in its BEACON trial.
Beam Therapeutics expects to submit risto-cel's BLA as early as year-end 2026. It ended the third quarter with $1.0 billion in cash, cash equivalents and marketable securities, with runway expected into mid-2029.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BEAM
this stock
Beam Therapeutics Inc.
|
$2.16B | -24.6% | +33.3% | — | 25.2% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BEAM | -8.5% | -13.1% | -27.8% | -23.3% | -24.6% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +0.1% | -3.9% | -18.7% | -14.5% | -25.8% |